Whiterabbit, Creator of AI to Improve and Streamline Breast Cancer Diagnoses, Emerges from Stealth to Announce New CEO and FDA Clearance
Startup s AI technology increases breast cancer screening compliance and empowers radiologists to interpret results faster, improving patient experience and outcomes
News provided by
Share this article
Share this article
SANTA CLARA, Calif., May 11, 2021 /PRNewswire/ Whiterabbit, an AI technology company focused on early breast cancer detection, today announced the appointment of Alexander Sardiña, MD as its new CEO and the recent FDA clearance of its first medical software product, WRDensity. Whiterabbit delivers on the three factors critical to eradicating late-stage breast cancer ensuring timely screening through improved compliance, expediting result turnaround times, and providing radiologists with AI-supported tools that enhance clinical outcomes.
Breast Cancer AI Company Whiterabbit Receives FDA Clearance for WRDensity
Startup’s AI technology increases breast cancer screening compliance and empowers radiologists to interpret results faster, improving patient experience and outcomes
May 11, 2021 Whiterabbit, an AI technology company focused on early breast cancer detection, today announced the appointment of Alexander Sardiña, M.D., as its new CEO and the recent FDA clearance of its first medical software product, WRDensity. Whiterabbit delivers on the three factors critical to eradicating late-stage breast cancer ensuring timely screening through improved compliance, expediting result turnaround times, and providing radiologists with AI-supported tools that enhance clinical outcomes.